Processing

Please wait...

Settings

Settings

Goto Application

1. KR1020080012449 - SAFE AND ACCURATE DIAGNOSTIC METHODS FOR SARS BY USING NUCLEOCAPSIDE OR SPIKE PROTEIN OF SARS-CoV MUTATED CORONAVIRUS AS AN ANTIGEN

Office Republic of Korea
Application Number 1020060073275
Application Date 03.08.2006
Publication Number 1020080012449
Publication Date 12.02.2008
Publication Kind A
IPC
G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
CPC
G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
G01N 33/535
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
531Production of immunochemical test materials
532Production of labelled immunochemicals
535with enzyme label ; or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
G01N 33/553
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
551the carrier being inorganic
553Metal or metal coated
G01N 33/577
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
577involving monoclonal antibodies ; binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens;
Applicants SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION
재단법인서울대학교산학협력재단
Inventors PARK, JAE HAK
박재학
Agents 김순웅
Title
(EN) SAFE AND ACCURATE DIAGNOSTIC METHODS FOR SARS BY USING NUCLEOCAPSIDE OR SPIKE PROTEIN OF SARS-CoV MUTATED CORONAVIRUS AS AN ANTIGEN
(KO) 뉴클레오캡시드 또는 스파이크 단백질을 이용한 사스진단방법
Abstract
(EN)
PURPOSE: Diagnostic methods for SARS(severe acute respiratory syndrome) by using nucleocapside or spike protein are provided to improve the safety and accuracy of diagnosis and allow early diagnosis, so that they are applicable to general laboratories and hospitals without a risk of infection. CONSTITUTION: A method for diagnosis of SARS comprises the steps of: amplifying a gene encoding SARS-CoV-N(SARS coronavirus-nucleocapsid protein) and amplifying the amplified gene to Escherichia coli to produce an SARS-CoV-N antigen; producing an antibody against the SARS-CoV-N antigen; and reacting a specimen containing the SARS-CoV-N antibody coupled with a coloring material such as enzyme or gold and the SARS-CoV antigen with a membrane adsorbing the SARS-CoV-N antibody. A diagnostic kit contains the membrane adsorbing the SARS-CoV-N antibody and solution containing the SARS-CoV-N antibody coupled with a coloring material. A method for preparing SARS-CoV-S(SARS coronavirus-spike protein) antigen comprises the steps of: amplifying a gene encoding SARS-CoV-S antigen and inserting the amplified gene into a vector; transfecting 293 T cell with an expression vector containing SARS-CoV-S antigen; and infecting the transformed 293 T cell with VSV(vesicular stomatitis vesicle) to produce SARS-CoV-S antigen. Further, the antibody is a single clone antibody. ©KIPO 2008

(KO)
본 발명은 뉴클레오캡시드 또는 스파이크 단백질을 이용한 SARS 진단방법에 관한 것으로, 더욱 상세하게는 본 발명은 E. coli 시스템을 이용하여 SARS-CoV-N항원을 생산하거나 VSV (Vesicular stomatitis virus) 시스템을 이용하여 스파이크 (Spike) 항원을 생산하는 모조(pseudotype)의 VSV를 제작함으로써 일반실험실 및 임상에서도 중화 항체가의 검사를 가능하게 하여 안전하고 신속한 SARS 진단 방법을 제공한다.